Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-025692

Karyopharm Therapeutics Inc. · KPTI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael Kauffman
Officer — Chief Executive Officer · Director
Period of report
Apr 18, 2018
Accepted (ET)
Apr 20, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockApr 18, 2018M10,000$0.264A522,143D
Common StockF2Apr 18, 2018S10,000$14.7878D512,143D
Common Stockholding———713,510IBy Spouse
Common StockF3holding———47,309IBy GRAT
Common StockF4holding———47,309IBy Spouse's GRAT

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F5$0.264Apr 18, 2018M2,424D—Dec 13, 2021Common Stock2,4240D
Stock Option (right to buy)F6$0.264Apr 18, 2018M7,576D—Dec 13, 2021Common Stock7,57618,181D

Explanation of responses